Novel therapies and vaccines against the human respiratory syncytial virus

dc.date.accessioned2020-04-20T19:47:26Z
dc.date.accessioned2022-10-18T23:09:06Z
dc.date.available2020-04-20T19:47:26Z
dc.date.available2022-10-18T23:09:06Z
dc.date.created2020-04-20T19:47:26Z
dc.date.issued2015
dc.identifierhttp://hdl.handle.net/10533/241708
dc.identifier3140455
dc.identifierWOS:000365724700001
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/4473042
dc.description.abstractIntroduction: Human respiratory syncytial virus (hRSV) is the leading cause of acute lower respiratory tract infections worldwide in infants, as well as an important pathogen affecting the elderly and immunocompromised individuals. Despite more than a hal
dc.languageeng
dc.relationhttps://doi.org/10.1517/13543784.2015.1099626
dc.relation10.1517/13543784.2015.1099626
dc.titleNovel therapies and vaccines against the human respiratory syncytial virus
dc.typeArticulo


Este ítem pertenece a la siguiente institución